BioSpace News Archive

Acasti Pharma Inc. today announced that the Company has aligned with the U.S. Food and Drug Administration (FDA) on the protocol for its pivotal Phase 3 trial of GTX-104 and the FDA also provided guidance for a potential GTX-104 New Drug Application (NDA) package.

The human brain, specifically its outermost cortex, is riddled with folds or ‘gyri’ essential for its proper functioning. Unsurprisingly, therefore, abnormal gyrification i.e., the development of gyri, can manifest as serious neurological disorders, including the highly disabling and widespread mental illness—major depressive disorder (MDD).

Infinity Pharmaceuticals, Inc. announced today that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that Infinity stockholders vote FOR the merger with MEI Pharma, Inc.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET.

IAS – the International AIDS Society – in partnership with Gilead Sciences, announced 18 Champions of the 2023 Me and My Healthcare Provider (MMHCP) campaign from Brazil, Hong Kong, Mexico and Taiwan.

Nymox Pharmaceutical Corporation received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company’s shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.

Genomma Lab Internacional, S.A.B. de C.V., announced that it will report its Second Quarter 2023 results on Wednesday, July 26, 2023 after the Mexican Market close.

Brii Biosciences Limited provided updates on its diverse pipeline of infectious disease and central nervous system disease candidates and announced a pivotal leadership transition that will further advance its strategic priorities.

10x Genomics, Inc. announced that its single-cell genomic technologies were used in a study published in the journal Nature Medicine about new gene signatures that explain why some children with leukemia have longer remission after CAR T-cell therapy.